Syros Announces Strategic Priorities and Expected Milestones
Retrieved on:
Sunday, January 6, 2019
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expected upcoming milestones.
Key Points:
- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expected upcoming milestones.
- 2018 was a great year for Syros, said Nancy Simonian, M.D., Syros chief executive officer.
- Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines.
- Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.